961 related articles for article (PubMed ID: 33193316)
1. Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer-A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research.
Zwing N; Failmezger H; Ooi CH; Hibar DP; Cañamero M; Gomes B; Gaire F; Korski K
Front Immunol; 2020; 11():550250. PubMed ID: 33193316
[TBL] [Abstract][Full Text] [Related]
2. Immunogenomic pathways associated with cytotoxic lymphocyte infiltration and survival in colorectal cancer.
Shen Y; Guan Y; Hummel JJ; Shyu CR; Mitchem JB
BMC Cancer; 2020 Feb; 20(1):124. PubMed ID: 32059711
[TBL] [Abstract][Full Text] [Related]
3. Colorectal Cancer-Associated Immune Exhaustion Involves T and B Lymphocytes and Conventional NK Cells and Correlates With a Shorter Overall Survival.
Sorrentino C; D'Antonio L; Fieni C; Ciummo SL; Di Carlo E
Front Immunol; 2021; 12():778329. PubMed ID: 34975867
[TBL] [Abstract][Full Text] [Related]
4. Systemic Inflammation Associates With a Myeloid Inflamed Tumor Microenvironment in Primary Resected Colon Cancer-May Cold Tumors Simply Be Too Hot?
Køstner AH; Nielsen PS; Georgsen JB; Parner ET; Nielsen MB; Kersten C; Steiniche T
Front Immunol; 2021; 12():716342. PubMed ID: 34531864
[TBL] [Abstract][Full Text] [Related]
5. Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer.
Zadka Ł; Chabowski M; Grybowski D; Piotrowska A; Dzięgiel P
Cancer Immunol Immunother; 2021 Sep; 70(9):2681-2700. PubMed ID: 33625532
[TBL] [Abstract][Full Text] [Related]
6. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile.
Krijgsman D; de Vries NL; Skovbo A; Andersen MN; Swets M; Bastiaannet E; Vahrmeijer AL; van de Velde CJH; Heemskerk MHM; Hokland M; Kuppen PJK
Cancer Immunol Immunother; 2019 Jun; 68(6):1011-1024. PubMed ID: 31053876
[TBL] [Abstract][Full Text] [Related]
7. Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer.
Chen H; Yao J; Bao R; Dong Y; Zhang T; Du Y; Wang G; Ni D; Xun Z; Niu X; Ye Y; Li HB
Mol Cancer; 2021 Feb; 20(1):29. PubMed ID: 33557837
[TBL] [Abstract][Full Text] [Related]
8. Immune Profiling of Deficient Mismatch Repair Colorectal Cancer Tumor Microenvironment Reveals Different Levels of Immune System Activation.
Giannini R; Zucchelli G; Giordano M; Ugolini C; Moretto R; Ambryszewska K; Leonardi M; Sensi E; Morano F; Pietrantonio F; Cremolini C; Falcone A; Fontanini G
J Mol Diagn; 2020 May; 22(5):685-698. PubMed ID: 32173570
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
11. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
Leivonen SK; Pollari M; Brück O; Pellinen T; Autio M; Karjalainen-Lindsberg ML; Mannisto S; Kellokumpu-Lehtinen PL; Kallioniemi O; Mustjoki S; Leppä S
Haematologica; 2019 Feb; 104(2):338-346. PubMed ID: 30237271
[TBL] [Abstract][Full Text] [Related]
12. OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer.
Weixler B; Cremonesi E; Sorge R; Muraro MG; Delko T; Nebiker CA; Däster S; Governa V; Amicarella F; Soysal SD; Kettelhack C; von Holzen UW; Eppenberger-Castori S; Spagnoli GC; Oertli D; Iezzi G; Terracciano L; Tornillo L; Sconocchia G; Droeser RA
Oncotarget; 2015 Nov; 6(35):37588-99. PubMed ID: 26439988
[TBL] [Abstract][Full Text] [Related]
13. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of CD8+ T-cells density in stage III colorectal cancer depends on SDF-1 expression.
Lalos A; Tülek A; Tosti N; Mechera R; Wilhelm A; Soysal S; Daester S; Kancherla V; Weixler B; Spagnoli GC; Eppenberger-Castori S; Terracciano L; Piscuoglio S; von Flüe M; Posabella A; Droeser RA
Sci Rep; 2021 Jan; 11(1):775. PubMed ID: 33436863
[TBL] [Abstract][Full Text] [Related]
15. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.
Tumino N; Besi F; Martini S; Di Pace AL; Munari E; Quatrini L; Pelosi A; Fiore PF; Fiscon G; Paci P; Scordamaglia F; Covesnon MG; Bogina G; Mingari MC; Moretta L; Vacca P
Front Immunol; 2021; 12():803014. PubMed ID: 35116033
[TBL] [Abstract][Full Text] [Related]
16. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
Li F; Zhao Y; Wei L; Li S; Liu J
Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
[TBL] [Abstract][Full Text] [Related]
17. Follistatin-Like 3 Correlates With Lymph Node Metastasis and Serves as a Biomarker of Extracellular Matrix Remodeling in Colorectal Cancer.
Yang C; Cao F; Huang S; Zheng Y
Front Immunol; 2021; 12():717505. PubMed ID: 34335633
[TBL] [Abstract][Full Text] [Related]
18. Correlation between immune signature and high-density lipoprotein cholesterol level in stage II/III colorectal cancer.
Wang Y; Sun XQ; Lin HC; Wang DS; Wang ZQ; Shao Q; Wang FH; Yan SM; Liang JY; Zeng ZL; Ju HQ; Xu RH; Li YH
Cancer Med; 2019 Mar; 8(3):1209-1217. PubMed ID: 30729718
[TBL] [Abstract][Full Text] [Related]
19. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: a retrospective study.
Shibutani M; Maeda K; Nagahara H; Fukuoka T; Matsutani S; Kashiwagi S; Tanaka H; Hirakawa K; Ohira M
BMC Cancer; 2018 Apr; 18(1):371. PubMed ID: 29614981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
